Ask My Investor AI
Public company · NYSEPublished company research
SYK

Identity verified against Stryker Corporation's SEC Form 10-Q for the quarter ended March 31, 2026, CIK 0000310764.

Stryker Corporation

Stryker reports a large Orthopaedics segment spanning knees, hips, trauma and extremities, orthopaedic technology and spinal implants. In Q1 2026, Orthopaedics net sales were $2.813 billion; knees were $670 million and hips were $460 million. These products can support mobility, but Stryker does not report an aging-in-place revenue category, so the demographic linkage remains analytical and NOT_READY pending human review.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
SYK
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0000310764
Investment case

How this company captures the theme economics

Competitive position

The Q1 2026 filing shows broad orthopaedic product coverage and reported growth in knees, hips, trauma and extremities, and orthopaedic technology. The filing directly supports product scale, not a comparative market-share conclusion.

Scarce assets

The reviewed filing supports a broad orthopaedic portfolio and segment scale. Procedure capacity, surgeon adoption, robotic pull-through and implant switching costs require separate primary-source review before they can be treated as scarce-asset conclusions.

Products, segments, and customers

Stryker reports MedSurg and Neurotechnology and Orthopaedics. Orthopaedics includes knees, hips, trauma and extremities, orthopaedic technology and spinal implants.

Theme capture

Orthopaedics represented $2.813 billion of Stryker's $6.020 billion Q1 2026 net sales. The reviewed filing supports mobility-related product exposure, but it does not quantify revenue attributable to older adults or aging in place.

Conditions

What must be true

  1. Orthopaedic procedure demand and product adoption must support durable growth after separating currency, acquisitions and divestitures.
  2. A human reviewer must confirm that mobility-related exposure is sufficiently material to the Aging in Place thesis without treating an inferred demographic link as issuer-reported fact.

Identifiable catalysts

  • Quarterly evidence on Orthopaedics unit volume, pricing and segment margin
  • Primary-source evidence on robotic-platform adoption and implant pull-through
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Mobility and orthopaedic devices, including hip and knee reconstruction, trauma and enabling technology.

Aging-in-place economy

Q1 2026 Orthopaedics net sales were $2.813 billion. Knees were $670 million, hips were $460 million, and the filing attributed underlying constant-currency growth across Orthopaedics businesses to increased unit volume after excluding acquisitions and divestitures.

Evidence
The SEC filing directly supports the segment and product-category figures. It does not attribute revenue to aging in place or quantify older-adult demand; that linkage is analytical and remains NOT_READY.
Materiality
disclosed — Orthopaedics is a disclosed segment representing $2.813 billion of $6.020 billion Q1 2026 net sales; aging-in-place attribution is not disclosed.
Financial evidence

Official SEC filing evidence

Reference period: Q1 2026.

  • Net sales$6.020 billion
    Q1 2026[2]
  • Reported net-sales growth2.6%
    Q1 2026[2]
  • Orthopaedics net sales$2.813 billion
    Q1 2026[2]
  • Knees net sales$670 million
    Q1 2026[2]
  • Hips net sales$460 million
    Q1 2026[2]
  • Operating income$936 million
    Q1 2026[2]
  • Operating margin15.5%
    Q1 2026[2]
  • Orthopaedics operating margin30.1%
    Q1 2026[2]

Limitation: The SEC filing establishes current reported scale and operating performance. It does not establish aging-attributable revenue, comparative market share or current valuation.

Risks

Material risks and break conditions

Material risks

  • The Q1 2026 filing attributes higher manufacturing and supply-chain costs partly to idle production time related to a cybersecurity incident.
  • Orthopaedics reported growth and margin can be affected by procedure volumes, pricing, product mix, acquisitions, divestitures and foreign exchange.

Thesis-break conditions

  • Orthopaedics unit-volume growth fails to persist after acquisition, divestiture and currency effects are separated.
  • Primary research fails to establish a material, durable connection between Stryker's mobility products and the Aging in Place thesis.
Investability conclusion

Where the evidence lands

Current SEC evidence supports identity, orthopaedic product exposure and reported financial scale. Theme attribution, competitive advantage, current valuation and human acceptance remain unresolved; the subject is NOT_READY.

Next diligence

  1. Quantify Mako adoption and implant pull-through from official evidence; separate unit volume, price, acquisitions, divestitures and currency; complete licensed valuation and independent human review.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Stryker Corporation FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-11 · accessed 2026-07-22
  2. Stryker Corporation Q1 2026 Form 10-QSEC EDGAR · primary · published 2026-05-11 · accessed 2026-07-29